Diabetic neuropathy: Clinical manifestations and current treatments

The Lancet Neurology

Volumn 11, Issue 6, 2012, Pages 521-534

  Callaghan, Brian C ^a   Cheng, Hsinlin T ^a   Stables, Catherine L ^a   Smith, Andrea L ^a   Feldman, Eva L ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; BENSERAZIDE; BOTULINUM TOXIN; CAPSAICIN; DESIPRAMINE; DEXTROMETHORPHAN; DULOXETINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GABAPENTIN; GLYCERYL TRINITRATE; ISOSORBIDE; LAMOTRIGINE; LEVODOPA; MAPROTILINE; MORPHINE; OXYCODONE; PARACETAMOL; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PREGABALIN; PROTEIN KINASE B; TEBANICLINE; TRAMADOL; VALPROIC ACID; VENLAFAXINE; ANTIDEPRESSANT AGENT; INSULIN; ISOSORBIDE DINITRATE; LIDOCAINE; OPIATE;

ANALGESIA; BLOOD GLUCOSE MONITORING; CLINICAL FEATURE; DIABETIC NEUROPATHY; GLUCOSE TOLERANCE; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LEG AMPUTATION; METABOLIC SYNDROME X; NERVE INJURY; NEUROPATHIC PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; PAIN; PARESTHESIA; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; POLYNEUROPATHY; PRIORITY JOURNAL; RETINOPATHY; REVIEW; TREATMENT DURATION; VESTIBULAR DISORDER; WEAKNESS; ALGORITHM; AUTONOMIC NEUROPATHY; DYSLIPIDEMIA; GLYCEMIC CONTROL; SIGNAL TRANSDUCTION;

DIABETIC NEUROPATHIES; HUMANS; RISK FACTORS;

EID: 84861111124     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(12)70065-0     Document Type: Review

References (132)

1. Bharucha NE, Bharucha AE, Bharucha EP Prevalence of peripheral neuropathy in the Parsi community of Bombay. Neurology 1991, 41:1315-1317.
2. Savettieri G, Rocca WA, Salemi G, et al. Prevalence of diabetic neuropathy with somatic symptoms: a door-to-door survey in two Sicilian municipalities. Sicilian Neuro-Epidemiologic Study (SNES) Group. Neurology 1993, 43:1115-1120.
3. Gregg EW, Sorlie P, Paulose-Ram R, et al. Prevalence of lower-extremity disease in the US adult population ≥40 years of age with and without diabetes: 1999-2000 national health and nutrition examination survey. Diabetes Care 2004, 27:1591-1597.
4. Johannsen L, Smith T, Havsager AM, et al. Evaluation of patients with symptoms suggestive of chronic polyneuropathy. J Clin Neuromuscul Dis 2001, 3:47-52.
5. Maser RE, Steenkiste AR, Dorman JS, et al. Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes 1989, 38:1456-1461.
6. Van Acker K, Bouhassira D, De Bacquer D, et al. Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes Metab 2009, 35:206-213.
7. Agrawal Y, Carey JP, Della Santina CC, Schubert MC, Minor LB Diabetes, vestibular dysfunction, and falls: analyses from the National Health and Nutrition Examination Survey. Otol Neurotol 2010, 31:1445-1450.
8. Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian JA The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care 2003, 26:1790-1795.
9. Margolis D, Malay DS, Hoffstad OJ, et al. Incidence of diabetic foot ulcer and lower extremity amputation among Medicare beneficiaries, 2006 to 2008. Data Points #2 2011, Agency for Healthcare Research and Quality, Rockville.
10. Barrett AM, Lucero MA, Le T, Robinson RL, Dworkin RH, Chappell AS Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: a review. Pain Med 2007, 8(suppl 2):S50-S62.
11. Daousi C, MacFarlane IA, Woodward A, Nurmikko TJ, Bundred PE, Benbow SJ Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med 2004, 21:976-982.
12. Galer BS, Gianas A, Jensen MP Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract 2000, 47:123-128.
13. Abbott CA, Malik RA, van Ross ER, Kulkarni J, Boulton AJ Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care 2011, 34:2220-2224.
14. Bennett MI, Attal N, Backonja MM, et al. Using screening tools to identify neuropathic pain. Pain 2007, 127:199-203.
15. Soedamah-Muthu SS, Chaturvedi N, Witte DR, Stevens LK, Porta M, Fuller JH Relationship between risk factors and mortality in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study (PCS). Diabetes Care 2008, 31:1360-1366.
16. Dyck PJ, Windebank AJ Diabetic and nondiabetic lumbosacral radiculoplexus neuropathies: new insights into pathophysiology and treatment. Muscle Nerve 2002, 25:477-491.
17. Thaisetthawatkul P, Dyck PJ Treatment of diabetic and nondiabetic lumbosacral radiculoplexus neuropathy. Curr Treat Options Neurol 2010, 12:95-99.
18. Gibbons CH, Freeman R Treatment-induced diabetic neuropathy: a reversible painful autonomic neuropathy. Ann Neurol 2010, 67:534-541.
19. Miralles-Garcia JM, de Pablos-Velasco P, Cabrerizo L, Perez M, Lopez-Gomez V Prevalence of distal diabetic polyneuropathy using quantitative sensory methods in a population with diabetes of more than 10 years' disease duration. Endocrinol Nutr 2010, 57:414-420.
20. Vincent AM, Hinder LM, Pop-Busui R, Feldman EL Hyperlipidemia: a new therapeutic target for diabetic neuropathy. J Peripher Nerv Syst 2009, 14:257-267.
21. Kim B, Feldman EL Insulin resistance in the nervous system. Trends Endocrinol Metab 2012, 23:133-141.
22. Sima AA, Zhang W, Grunberger G Type 1 diabetic neuropathy and C-peptide. Exp Diabesity Res 2004, 5:65-77.
23. Vincent AM, Callaghan BC, Smith AL, Feldman EL Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nat Rev Neurol 2011, 7:573-583.
24. Kim B, McLean LL, Philip SS, Feldman EL Hyperinsulinemia induces insulin resistance in dorsal root ganglion neurons. Endocrinology 2011, 152:3638-3647.
25. Vincent AM, Russell JW, Low P, Feldman EL Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr Rev 2004, 25:612-628.
26. Obrosova IG Increased sorbitol pathway activity generates oxidative stress in tissue sites for diabetic complications. Antioxid Redox Signal 2005, 7:1543-1552.
27. Sugimoto K, Yasujima M, Yagihashi S Role of advanced glycation end products in diabetic neuropathy. Curr Pharm Des 2008, 14:953-961.
28. Duran-Jimenez B, Dobler D, Moffatt S, et al. Advanced glycation end products in extracellular matrix proteins contribute to the failure of sensory nerve regeneration in diabetes. Diabetes 2009, 58:2893-2903.
29. Vincent AM, Perrone L, Sullivan KA, et al. Receptor for advanced glycation end products activation injures primary sensory neurons via oxidative stress. Endocrinology 2007, 148:548-558.
30. Bierhaus A, Nawroth PP Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologia 2009, 52:2251-2263.
31. Clemens A, Siegel E, Gallwitz B Global risk management in type 2 diabetes: blood glucose, blood pressure, and lipids-update on the background of the current guidelines. Exp Clin Endocrinol Diabetes 2004, 112:493-503.
32. Wiggin TD, Sullivan KA, Pop-Busui R, Amato A, Sima AA, Feldman EL Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes 2009, 58:1634-1640.
33. Padilla A, Descorbeth M, Almeyda AL, Payne K, De Leon M Hyperglycemia magnifies Schwann cell dysfunction and cell death triggered by PA-induced lipotoxicity. Brain Res 2011, 1370:64-79.
34. McCall KD, Holliday D, Dickerson E, et al. Phenylmethimazole blocks palmitate-mediated induction of inflammatory cytokine pathways in 3T3L1 adipocytes and RAW 264.7 macrophages. J Endocrinol 2010, 207:343-353.
35. Vincent AM, Hayes JM, McLean LL, Vivekanandan-Giri A, Pennathur S, Feldman EL Dyslipidemia-induced neuropathy in mice: the role of oxLDL/LOX-1. Diabetes 2009, 58:2376-2385.
36. Nowicki M, Muller K, Serke H, et al. Oxidized low-density lipoprotein (oxLDL)-induced cell death in dorsal root ganglion cell cultures depends not on the lectin-like oxLDL receptor-1 but on the toll-like receptor-4. J Neurosci Res 2010, 88:403-412.
37. Jang ER, Lee CS 7-ketocholesterol induces apoptosis in differentiated PC12 cells via reactive oxygen species-dependent activation of NF-kappaB and Akt pathways. Neurochem Int 2011, 58:52-59.
38. Toth C, Brussee V, Martinez JA, McDonald D, Cunningham FA, Zochodne DW Rescue and regeneration of injured peripheral nerve axons by intrathecal insulin. Neuroscience 2006, 139:429-449.
39. Xu QG, Li XQ, Kotecha SA, Cheng C, Sun HS, Zochodne DW Insulin as an in vivo growth factor. Exp Neurol 2004, 188:43-51.
40. Ekberg K, Johansson BL Effect of C-peptide on diabetic neuropathy in patients with type 1 diabetes. Exp Diabetes Res 2008, 2008:457912.
41. Tesch GH Role of macrophages in complications of type 2 diabetes. Clin Exp Pharmacol Physiol 2007, 34:1016-1019.
42. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986. The Diabetes Control and Complications Trial Research Group.
43. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853. UK Prospective Diabetes Study (UKPDS) Group.
44. Phillips LK, Prins JB The link between abdominal obesity and the metabolic syndrome. Curr Hypertens Rep 2008, 10:156-164.
45. Kalupahana NS, Moustaid-Moussa N The renin-angiotensin system: a link between obesity, inflammation and insulin resistance. Obes Rev 2012, 13:136-149.
46. Davidson EP, Coppey LJ, Holmes A, Yorek MA Effect of inhibition of angiotensin converting enzyme and/or neutral endopeptidase on vascular and neural complications in high fat fed/low dose streptozotocin-diabetic rats. Eur J Pharmacol 2012, 677:180-187.
47. Oltman CL, Davidson EP, Coppey LJ, Kleinschmidt TL, Dake B, Yorek MA Role of the effect of inhibition of neutral endopeptidase on vascular and neural complications in streptozotocin-induced diabetic rats. Eur J Pharmacol 2011, 650:556-562.
48. Cameron NE, Eaton SE, Cotter MA, Tesfaye S Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 2001, 44:1973-1988.
49. Novella SP, Inzucchi SE, Goldstein JM The frequency of undiagnosed diabetes and impaired glucose tolerance in patients with idiopathic sensory neuropathy. Muscle Nerve 2001, 24:1229-1231.
50. Singleton JR, Smith AG, Bromberg MB Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care 2001, 24:1448-1453.
51. Franklin GM, Kahn LB, Baxter J, Marshall JA, Hamman RF Sensory neuropathy in non-insulin-dependent diabetes mellitus. The San Luis Valley Diabetes Study. Am J Epidemiol 1990, 131:633-643.
52. Smith AG, Russell J, Feldman EL, et al. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care 2006, 29:1229-1294.
53. Hughes RA, Umapathi T, Gray IA, et al. A controlled investigation of the cause of chronic idiopathic axonal polyneuropathy. Brain 2004, 127:1723-1730.
54. Dyck PJ, Overland CJ, Davies JL, et al. Does impaired glycemia cause polyneuropathy and other diabetic complications?. J Peripheral Nervous Soc 2011, 16(suppl 3):30-31.
55. Karve A, Hayward RA Prevalence, diagnosis, and treatment of impaired fasting glucose and impaired glucose tolerance in nondiabetic U.S. adults. Diabetes Care 2010, 33:2355-2359.
56. Holman RR, Dornan TL, Mayon-White V, et al. Prevention of deterioration of renal and sensory-nerve function by more intensive management of insulin-dependent diabetic patients. A two-year randomised prospective study. Lancet 1983, 1:204-208.
57. Lauritzen T, Frost-Larsen K, Larsen HW, Deckert T Two-year experience with continuous subcutaneous insulin infusion in relation to retinopathy and neuropathy. Diabetes 1985, 34(suppl 3):74-79.
58. Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen KF, et al. Effect of near normoglycaemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: the Oslo study. Br Med J (Clin Res Ed) 1986, 293:1195-1199.
59. Jakobsen J, Christiansen JS, Kristoffersen I, et al. Autonomic and somatosensory nerve function after 2 years of continuous subcutaneous insulin infusion in type I diabetes. Diabetes 1988, 37:452-455.
60. Reichard P, Nilsson BY, Rosenqvist U The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993, 329:304-309.
61. Linn T, Ortac K, Laube H, Federlin K Intensive therapy in adult insulin-dependent diabetes mellitus is associated with improved insulin sensitivity and reserve: a randomized, controlled, prospective study over 5 years in newly diagnosed patients. Metabolism 1996, 45:1508-1513.
62. Kawamori R, Kamada T Determination of the glycemic threshold for the regression or prevention of diabetic microangiopathies, and the insulin injection regimen to establish strict glycemic control in NIDDM. Jpn J Med 1991, 30:618-621.
63. Tovi J, Svanborg E, Nilsson BY, Engfeldt P Diabetic neuropathy in elderly type 2 diabetic patients: effects of insulin treatment. Acta Neurol Scand 1998, 98:346-353.
64. Azad N, Emanuele NV, Abraira C, et al. The effects of intensive glycemic control on neuropathy in the VA cooperative study on type II diabetes mellitus (VA CSDM). J Diabetes Complications 1999, 13:307-313.
65. Shichiri M, Kishikawa H, Ohkubo Y, Wake N Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000, 23(suppl 2):B21-B29.
66. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003, 348:383-393.
67. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129-139.
68. Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010, 376:419-430.
69. Hotta N, Kawamori R, Sano T, Kakuta H, Kamada T, Sakamoto N Diabetic neuropathy: effects of intensified glycaemic control with multiple insulin injections. Diabet Med 1993, 10(suppl 2):91S-94S.
70. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995, 28:103-117.
71. Service FJ, Daube JR, O'Brien PC, et al. Effect of blood glucose control on peripheral nerve function in diabetic patients. Mayo Clin Proc 1983, 58:283-289.
72. Attal N, Cruccu G, Haanpaa M, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 2006, 13:1153-1169.
73. Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010, 17:1113-1123.
74. Bril V, England J, Franklin GM, et al. Evidence-based guideline: Treatment of painful diabetic neuropathy. Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2011, 76:1758-1765.
75. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 2004, 110:628-638.
76. Lesser H, Sharma U, LaMoreaux L, Poole RM Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 2004, 63:2104-2110.
77. Richter RW, Portenoy R, Sharma U, Lamoreaux L, Bockbrader H, Knapp LE Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain 2005, 6:253-260.
78. McGovern MP, Williams DJ, Hannaford PC, et al. Introduction of a new incentive and target-based contract for family physicians in the UK: good for older patients with diabetes but less good for women?. Diabet Med 2008, 25:1083-1089.
79. Arezzo JC, Rosenstock J, Lamoreaux L, Pauer L Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. BMC Neurol 2008, 8:33.
80. Tolle T, Freynhagen R, Versavel M, Trostmann U, Young JP Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur J Pain 2008, 12:203-213.
81. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998, 280:1831-1836.
82. Gorson KC, Schott C, Herman R, Ropper AH, Rand WM Gabapentin in the treatment of painful diabetic neuropathy: a placebo controlled, double blind, crossover trial. J Neurol Neurosurg Psychiatry 1999, 66:251-252.
83. Eisenberg E, Lurie Y, Braker C, Daoud D, Ishay A Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology 2001, 57:505-509.
84. Vinik AI, Tuchman M, Safirstein B, et al. Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double-blind, placebo-controlled studies. Pain 2007, 128:169-179.
85. Jose VM, Bhansali A, Hota D, Pandhi P Randomized double-blind study comparing the efficacy and safety of lamotrigine and amitriptyline in painful diabetic neuropathy. Diabet Med 2007, 24:377-383.
86. Kochar DK, Jain N, Agarwal RP, Srivastava T, Agarwal P, Gupta S Sodium valproate in the management of painful neuropathy in type 2 diabetes-a randomized placebo controlled study. Acta Neurol Scand 2002, 106:248-252.
87. Kochar DK, Rawat N, Agrawal RP, et al. Sodium valproate for painful diabetic neuropathy: a randomized double-blind placebo-controlled study. QJM 2004, 97:33-38.
88. Otto M, Bach FW, Jensen TS, Sindrup SH Valproic acid has no effect on pain in polyneuropathy: a randomized, controlled trial. Neurology 2004, 62:285-288.
89. Max MB, Culnane M, Schafer SC, et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology 1987, 37:589-596.
90. Morello CM, Leckband SG, Stoner CP, Moorhouse DF, Sahagian GA Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med 1999, 159:1931-1937.
91. Vrethem M, Boivie J, Arnqvist H, Holmgren H, Lindstrom T, Thorell LH A comparison a amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics. Clin J Pain 1997, 13:313-323.
92. Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992, 326:1250-1256.
93. Rowbotham MC, Goli V, Kunz NR, Lei D Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 2004, 110:697-706.
94. Kadiroglu AK, Sit D, Kayabasi H, Tuzcu AK, Tasdemir N, Yilmaz ME The effect of venlafaxine HCl on painful peripheral diabetic neuropathy in patients with type 2 diabetes mellitus. J Diabetes Complications 2008, 22:241-245.
95. Simpson DA Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy. J Clin Neuromuscul Dis 2001, 3:53-62.
96. Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005, 116:109-118.
97. Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005, 6:346-356.
98. Wernicke JF, Pritchett YL, D'Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006, 67:1411-1420.
99. Gimbel JS, Richards P, Portenoy RK Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology 2003, 60:927-934.
100. Hanna M, O'Brien C, Wilson MC Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. Eur J Pain 2008, 12:804-813.
101. Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005, 352:1324-1334.
102. Harati Y, Gooch C, Swenson M, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 1998, 50:1842-1846.
103. Sindrup SH, Andersen G, Madsen C, Smith T, Brosen K, Jensen TS Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial. Pain 1999, 83:85-90.
104. Freeman R, Raskin P, Hewitt DJ, et al. Randomized study of tramadol/acetaminophen versus placebo in painful diabetic peripheral neuropathy. Curr Med Res Opin 2007, 23:147-161.
105. Sang CN, Booher S, Gilron I, Parada S, Max MB Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trials. Anesthesiology 2002, 96:1053-1061.
106. Nelson KA, Park KM, Robinovitz E, Tsigos C, Max MB High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology 1997, 48:1212-1218.
107. Effect of treatment with capsaicin on daily activities of patients with painful diabetic neuropathy. Diabetes Care 1992, 15:159-165. Capsaicin Study Group.
108. Tandan R, Lewis GA, Krusinski PB, Badger GB, Fries TJ Topical capsaicin in painful diabetic neuropathy. Controlled study with long-term follow-up. Diabetes Care 1992, 15:8-14.
109. Yuen KC, Baker NR, Rayman G Treatment of chronic painful diabetic neuropathy with isosorbide dinitrate spray: a double-blind placebo-controlled cross-over study. Diabetes Care 2002, 25:1699-1703.
110. Agrawal RP, Choudhary R, Sharma P, et al. Glyceryl trinitrate spray in the management of painful diabetic neuropathy: a randomized double blind placebo controlled cross-over study. Diabetes Res Clin Pract 2007, 77:161-167.
111. Rowbotham MC, Duan WR, Thomas J, Nothaft W, Backonja MM A randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of ABT-594 in patients with diabetic peripheral neuropathic pain. Pain 2009, 146:245-252.
112. Yuan RY, Sheu JJ, Yu JM, et al. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology 2009, 72:1473-1478.
113. Ertas M, Sagduyu A, Arac N, Uludag B, Ertekin C Use of levodopa to relieve pain from painful symmetrical diabetic polyneuropathy. Pain 1998, 75:257-259.
114. Saarto T, Wiffen PJ Antidepressants for neuropathic pain. Cochrane Database Syst Rev 2005, 3. CD005454.
115. Sindrup SH, Otto M, Finnerup NB, Jensen TS Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol 2005, 96:399-409.
116. Hanna FW, Peters JR, Harlow J, Jones PW Gestational diabetes screening and glycaemic management; national survey on behalf of the Association of British Clinical Diabetologists. QJM 2008, 101:777-784.
117. Eisenberg E, McNicol ED, Carr DB Efficacy of mu-opioid agonists in the treatment of evoked neuropathic pain: systematic review of randomized controlled trials. Eur J Pain 2006, 10:667-676.
118. Hollingshead J, Dühmke RM, Cornblath DR Tramadol for neuropathic pain. Cochrane Database Syst Rev 2006, 19. CD003726.
119. Effect of treatment with capsaicin on daily activities of patients with painful diabetic neuropathy. Diabetes Care 1992, 15:159-165. The Capsaicin Study G.
120. Kastrup J, Angelo H, Petersen P, Dejgård A, Hilsted J Treatment of chronic painful diabetic neuropathy with intravenous lidocaine infusion. Br Med J (Clin Res Ed) 1986, 18:173.
121. Viola V, Newnham HH, Simpson RW Treatment of intractable painful diabetic neuropathy with intravenous lignocaine. J Diabetes Complications 2006, 20:34-39.
122. Jensen TS, Backonja MM, Hernandez Jimenez S, Tesfaye S, Valensi P, Ziegler D New perspectives on the management of diabetic peripheral neuropathic pain. Diab Vasc Dis Res 2006, 3:108-119.
123. Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010, 85(suppl 3):S3-14.
124. Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007, 132:237-251.
125. Isomaa B, Henricsson M, Almgren P, Tuomi T, Taskinen MR, Groop L The metabolic syndrome influences the risk of chronic complications in patients with type II diabetes. Diabetologia 2001, 44:1148-1154.
126. Bonadonna RC, Cucinotta D, Fedele D, Riccardi G, Tiengo A The metabolic syndrome is a risk indicator of microvascular and macrovascular complications in diabetes: results from Metascreen, a multicenter diabetes clinic-based survey. Diabetes Care 2006, 29:2701-2707.
127. Costa LA, Canani LH, Lisboa HR, Tres GS, Gross JL Aggregation of features of the metabolic syndrome is associated with increased prevalence of chronic complications in type 2 diabetes. Diabet Med 2004, 21:252-255.
128. Cull CA, Jensen CC, Retnakaran R, Holman RR Impact of the metabolic syndrome on macrovascular and microvascular outcomes in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study 78. Circulation 2007, 116:2119-2126.
129. Smith AG, Rose K, Singleton JR Idiopathic neuropathy patients are at high risk for metabolic syndrome. J Neurol Sci 2008, 273:25-28.
130. Straub RH, Elbracht R, Kramer BK, Roth M, Palitzsch KD, Scholmerich J Influence of digoxin-like immunoreactive factor on late complications in patients with diabetes mellitus. Eur J Clin Invest 1994, 24:482-487.
131. Tesfaye S, Chaturvedi N, Eaton SE, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005, 352:341-350.
132. De Block CE, De Leeuw IH, Van Gaal LF Impact of overweight on chronic microvascular complications in type 1 diabetic patients. Diabetes Care 2005, 28:1649-1655.